| $337M | ||
| $259M | ||
| $79M | ||
| $60M | ||
| $58M | ||
| $50M |
Buys | $0 | 0 | 0 |
Sells | $4,373,484 | 17 | 100 |
| Scadden David | director | 0 | $0 | 1 | $9,256 | $-9,256 |
| Milanova Tsveta | Chief Commercial Officer | 0 | $0 | 2 | $149,975 | $-149,975 |
| Washburn Theodore James Jr. | Principal Accounting Officer | 0 | $0 | 3 | $180,254 | $-180,254 |
| FOUSE JACQUALYN A | director | 0 | $0 | 1 | $194,172 | $-194,172 |
| Jones Cecilia | Chief Financial Officer | 0 | $0 | 2 | $205,488 | $-205,488 |
| Gheuens Sarah | Chief Medical Officer | 0 | $0 | 2 | $304,802 | $-304,802 |
| Goff Brian | Chief Executive Officer | 0 | $0 | 2 | $934,277 | $-934,277 |
| Ballal Rahul D. | director | 0 | $0 | 2 | $1.12M | $-1.12M |
| Burns James William | Chief Legal Officer | 0 | $0 | 2 | $1.28M | $-1.28M |
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Over the last 12 months, insiders at Agios Pharmaceuticals, Inc. have bought $0 and sold $4.37M worth of Agios Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Agios Pharmaceuticals, Inc. have bought $0 and sold $4.86M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 40,322 shares for transaction amount of $1.25M was made by FOUSE JACQUALYN A (Chief Executive Officer) on 2019‑11‑13.
| 2025-04-10 | Sale | FOUSE JACQUALYN A | director | 7,497 0.0131% | $25.90 | $194,172 | +16.48% | |
| 2025-03-03 | Sale | Goff Brian | Chief Executive Officer | 12,947 0.0244% | $35.54 | $460,136 | -8.80% | |
| 2025-03-03 | Sale | Gheuens Sarah | Chief Medical Officer | 4,005 0.0075% | $35.54 | $142,338 | -8.80% | |
| 2025-03-03 | Sale | Milanova Tsveta | Chief Commercial Officer | 1,681 0.0032% | $35.54 | $59,743 | -8.80% | |
| 2025-03-03 | Sale | Jones Cecilia | Chief Financial Officer | 2,275 0.0043% | $35.54 | $80,854 | -8.80% | |
| 2025-03-03 | Sale | Burns James William | Chief Legal Officer | 4,005 0.0075% | $35.54 | $142,338 | -8.80% | |
| 2025-03-03 | Sale | Washburn Theodore James Jr. | Principal Accounting Officer | 1,655 0.0031% | $35.54 | $58,819 | -8.80% | |
| 2025-02-05 | Sale | Washburn Theodore James Jr. | Principal Accounting Officer | 2,272 0.004% | $34.39 | $78,134 | -10.03% | |
| 2025-01-06 | Sale | Milanova Tsveta | Chief Commercial Officer | 2,804 0.0047% | $32.18 | $90,233 | -4.62% | |
| 2024-12-11 | Sale | Scadden David | director | 200 0.0004% | $46.28 | $9,256 | -25.06% | |
| 2024-11-08 | Sale | Ballal Rahul D. | director | 10,000 0.0432% | $58.19 | $581,911 | -43.58% | |
| 2024-11-08 | Sale | Washburn Theodore James Jr. | Principal Accounting Officer | 772 0.0032% | $56.09 | $43,301 | -43.58% | |
| 2024-11-07 | Sale | Burns James William | Chief Legal Officer | 21,752 0.0844% | $52.21 | $1.14M | -39.44% | |
| 2024-11-07 | Sale | Ballal Rahul D. | director | 10,000 0.0398% | $53.52 | $535,236 | -39.44% | |
| 2024-09-26 | Sale | Jones Cecilia | Chief Financial Officer | 2,542 0.0093% | $49.03 | $124,634 | -29.27% | |
| 2024-08-08 | Sale | Goff Brian | Chief Executive Officer | 11,091 0.0352% | $42.75 | $474,140 | -21.33% | |
| 2024-07-01 | Sale | Gheuens Sarah | Chief Medical Officer | 3,705 0.0121% | $43.85 | $162,464 | -17.24% | |
| 2024-06-05 | Sale | Goff Brian | Chief Executive Officer | 12,115 0.044% | $48.84 | $591,697 | -14.39% | |
| 2024-06-03 | Sale | Washburn Theodore James Jr. | Principal Accounting Officer | 1,362 0.0045% | $44.39 | $60,459 | -4.20% | |
| 2024-04-10 | Sale | FOUSE JACQUALYN A | director | 7,791 0.0159% | $27.55 | $214,642 | +40.35% |
| FOUSE JACQUALYN A | director | 149220 0.2577% | $5.12M | 1 | 5 | +28.93% |
| Goff Brian | Chief Executive Officer | 83139 0.1436% | $2.85M | 0 | 8 | |
| Gheuens Sarah | Chief Medical Officer | 47098 0.0813% | $1.62M | 0 | 7 | |
| Milanova Tsveta | Chief Commercial Officer | 22892 0.0395% | $785,195.60 | 0 | 5 | |
| Jones Cecilia | Chief Financial Officer | 21843 0.0377% | $749,214.90 | 0 | 6 | |
| Burns James William | Chief Legal Officer | 18650 0.0322% | $639,695.00 | 0 | 8 | |
| Scadden David | director | 15483 0.0267% | $531,066.90 | 1 | 1 | <0.0001% |
| Ballal Rahul D. | director | 7992 0.0138% | $274,125.60 | 0 | 2 | |
| Washburn Theodore James Jr. | Principal Accounting Officer | 6038 0.0104% | $207,103.40 | 0 | 15 | |
| Celgene European Investment Co LLC | 10 percent owner | 1856353 3.2053% | $63.67M | 4 | 0 | +32.26% |
| CELGENE CORP /DE/ | 10 percent owner | 1777824 3.0697% | $60.98M | 2 | 0 | +14.63% |
| Schenkein David P | director | 122854 0.2121% | $4.21M | 1 | 58 | +28.93% |
| Tessier-Lavigne Marc | director | 101009 0.1744% | $3.46M | 1 | 0 | <0.0001% |
| Cantley Lewis Clayton Jr. | director | 79475 0.1372% | $2.73M | 0 | 60 | |
| Higgons John Duncan | Chief Operating Officer | 61835 0.1068% | $2.12M | 0 | 31 | |
| MARAGANORE JOHN | director | 36209 0.0625% | $1.24M | 4 | 2 | +52.79% |
| Biller Scott | Chief Scientific Officer | 26511 0.0458% | $909,327.30 | 0 | 58 | |
| Bowden Christopher | Chief Medical Officer | 15487 0.0267% | $531,204.10 | 0 | 26 | |
| Hoerter Steven L. | Chief Commercial Officer | 10941 0.0189% | $375,276.30 | 0 | 10 | |
| Miles Darrin | Chief Commercial Officer | 7209 0.0124% | $247,268.70 | 0 | 3 | |
| Foster-Cheek Kaye I | director | 5524 0.0095% | $189,473.20 | 0 | 6 | |
| NELSEN ROBERT | director | 0 0% | $0 | 0 | 7 | |
| Goddard Glenn | Senior Vice President, Finance | 0 0% | $0 | 0 | 22 | |
| Alenson Carman | Principal Accounting Officer | 0 0% | $0 | 0 | 12 |
$66,492,695 | 135 | 27.65% | $2.17B | |
$193,151,375 | 134 | 8.18% | $1.86B | |
$20,363,540 | 75 | 100.86% | $2.17B | |
$1,376,668 | 53 | 18.46% | $2.15B | |
$150,253,463 | 26 | -52.83% | $1.65B | |
$1,801,511 | 23 | 18.58% | $2.17B | |
$174,105,409 | 15 | 10.88% | $2.37B | |
Agios Pharmaceuticals, Inc. (AGIO) | $154,554,190 | 14 | 29.60% | $1.99B |
$1,248,715 | 10 | 5.66% | $2.07B | |
$45,445,266 | 9 | -24.96% | $1.94B | |
$32,575,266 | 8 | 37.03% | $1.72B | |
$25,073,947 | 7 | -5.99% | $1.89B | |
$91,325,021 | 6 | 1.83% | $1.64B | |
$142,493,653 | 3 | 4.30% | $2.07B | |
$103,599,972 | 2 | -36.81% | $1.97B | |
$276,224 | 2 | -7.04% | $2.27B | |
$7,600,000 | 1 | -4.05% | $1.97B | |
$10,000,009 | 1 | 100.92% | $1.86B | |
$9,900,000 | 1 | -7.19% | $2.11B |
| Increased Positions | 111 | +41.42% | 8M | +12.9% |
| Decreased Positions | 119 | -44.4% | 7M | -12.34% |
| New Positions | 38 | New | 4M | New |
| Sold Out Positions | 42 | Sold Out | 5M | Sold Out |
| Total Postitions | 260 | -2.99% | 60M | +0.56% |
| Farallon Capital Management Llc | $170,801.00 | 9.78% | 5.67M | +13,600 | +0.24% | 2024-12-31 |
| Vanguard Group Inc | $169,503.00 | 9.71% | 5.63M | +85,339 | +1.54% | 2024-12-31 |
| Blackrock, Inc. | $153,773.00 | 8.81% | 5.11M | +92,486 | +1.84% | 2025-03-31 |
| Bellevue Group Ag | $105,806.00 | 6.06% | 3.52M | -220,765 | -5.91% | 2024-12-31 |
| Price T Rowe Associates Inc /Md/ | $72,948.00 | 4.18% | 2.42M | -408,975 | -14.44% | 2024-12-31 |
| Armistice Capital, Llc | $68,156.00 | 3.9% | 2.26M | +57,234 | +2.59% | 2024-12-31 |
| State Street Corp | $64,784.00 | 3.71% | 2.15M | -179,156 | -7.68% | 2024-12-31 |
| Erste Asset Management Gmbh | $60,498.00 | 3.47% | 2.01M | -175,000 | -8.01% | 2024-12-31 |
| Macquarie Group Ltd | $50,718.00 | 2.91% | 1.68M | -5,808 | -0.34% | 2024-12-31 |
| Jefferies Financial Group Inc. | $45,150.00 | 2.59% | 1.5M | +2M | New | 2024-12-31 |